- Posts: 1127
- Thank you received: 276
1. You must be a registered website user in order to post and comment. Guests may read only.
2. Be kind and helpful, not rude and cynical.
3. Don't advertise or promote anything. You will be banned from the group.
4. Report problems to the moderators. THANK YOU!
www.ncbi.nlm.nih.gov/pubmed/23686644
J Thromb Thrombolysis. 2013 May 18. [Epub ahead of print]
Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group.
Sakamoto K, Nakasone H, Tsurumi S, Sasaki K, Mitani K, Kida M, Hangaishi A, Usuki K, Kobayashi A, Sato K, Karasawa-Yamaguchi M, Izutsu K, Okoshi Y, Chiba S, Kanda Y.
Author information: Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama, Saitama, 330-8503, Japan.
Abstract:
High-dose dexamethasone (HDD) has been shown to be an effective initial treatment for immune thrombocytopenia (ITP), but it is not clear whether HDD offers any advantages over conventional-dose prednisone (PSL). We retrospectively compared the efficacy and toxicity of HDD and PSL for newly diagnosed ITP. The response was evaluated according to the International Working Group (IWG) criteria. We analyzed data from 31 and 69 patients in the HDD and PSL groups, respectively. There were no significant differences in patient characteristics between the two groups except for the incidence of the eradication of Helicobacter pylori. The response rate was better in the HDD group (42.7 vs. 28.4 %), and this difference was statistically significant when adjusted for other factors including the eradication of H. pylori. In the HDD group, a response was achieved earlier (28 vs. 152 days in median) and steroids were more frequently discontinued at 6 months (64.5 vs. 37.7 %). Among patients who achieved a response, there was no significant difference in the incidence of loss of response. There were no significant differences in the rate of adverse events, transition to chronic ITP, and splenectomy. In conclusion, HDD might enable the early cessation of steroids without a loss of response.
PMID: 23686644 [PubMed - as supplied by publisher]
www.ncbi.nlm.nih.gov/pubmed/1961352
Effect of high-dose dexamethasone in prednisone-resistant autoimmune thrombocytopenic purpura (ITP).
Neth J Med 1991 Aug;39(1-2):6-10 P Dubbeld, C van der Heul, H F Hillen
This study investigated whether high-dose dexamethasone pulse therapy could bring about a remission in adult chronic idiopathic thrombocytopenic purpura (ITP) patients who had not achieved a remission on the usual prednisone therapy. Newly diagnosed patients with ITP received the usual prednisone therapy, 1 mg/kg/day, for 3 weeks, after which period the dosage was tapered off. If after 6 weeks of treatment the platelets were less than 50 x 10(9)/l the prednisone therapy was considered a failure and 200 mg dexamethasone i.v. was given on 3 consecutive days. Six of the twenty-five patients with newly diagnosed ITP treated according to this protocol achieved a sufficient response with prednisone therapy. Nineteen patients were resistant to or relapsed during prednisone therapy and were treated with high-dose dexamethasone. Four of these nineteen patients showed a sufficient response. Three are still in remission. As no serious adverse effects were observed, high-dose dexamethasone therapy can be considered before splenectomy in prednisone- resistant ITP patients.
Affiliation
Department of Internal Medicine, Sint Elisabeth Hospital, Tilburg, The Netherlands.
Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience
www.bloodjournal.org/content/109/4/1401.full?sso-checked=true
.In the monocenter study, 37 patients with severe ITP, age at least 20 years and no more than 65 years, were enrolled. HD-DXM was given in 4-day pulses every 28 days, for 6 cycles. Response rate was 89.2%; relapse-free survival (RFS) was 90% at 15 months; long-term responses, lasting for a median time of 26 months (range 6-77 months) were 25 of 37 (67.6%)
In the multicenter study, 95 patients with severe ITP, age at least 2 years and no more than 70 years, were enrolled. HD-DXM was given in 4-day pulses every 14 days, for 4 cycles; 90 patients completed 4 cycles. Response rate (85.6%) was similar in patients classified by age (< 18 years, 36 of 42 = 85.7%; ≥ 18 years, 41 of 48 = 85.4%, P = not significant), with a statistically significant difference between the second and third cycle (75.8% vs 89%, P = .018). RFS at 15 months 81%; long-term responses, lasting for a median time of 8 months (range 4-24 months) were 67 of 90 (74.4%)
No, just dex. Repeated 4 day X 40 mg high-dose dexamethasone pulses over multiple weeks.Sandi wrote: Do you mean combo treatments such as Dex and Rituxan?
Rob16 wrote: In either case, it is INTERMITTENT treatment over 4 or 6 cycles, NOT CONTINUOUS high dose treatment.
What they found was that counts stayed up LONGER if multiple cycles were used.
High-dose dexamethasone versus prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial
Yu Wei1, Xue-bin Ji1, Ya-wen Wang1, Jing-xia Wang2, En-qin Yang3, Zheng-cheng Wang4, Yu-qi Sang5, Zuo-mu Bi6, Cui-ai Ren7, Fang Zhou8, Guo-qiang Liu9, Jun Peng1, and Ming Hou1,*
Key Points
High-dose dexamethasone is a preferred strategy to conventional prednisone as first-line management of newly diagnosed adult primary ITP.
Abstract
This study compared the efficacy and safety of high-dose dexamethasone (HD-DXM) and conventional prednisone (PDN) on the largest cohort to date as first-line strategies for newly diagnosed adult primary immune thrombocytopenia (ITP). Patients enrolled were randomized to receive dexamethasone 40 mg/d for four days (n = 95, non-responders received an additional four-day course of dexamethasone), or prednisone 1.0 mg/kg daily for four weeks and then tapered (n = 97). One or two courses of HD-DXM resulted in a higher incidence of overall initial response (82.1% vs. 67.4%, P = 0.044) and complete response (50.5% vs. 26.8%, P = 0.001) compared to prednisone. Time to response was shorter in the HD-DXM arm (P < 0.001), and a baseline bleeding score ≥ 8 was associated with a decreased likelihood of initial response. Sustained response was achieved by 40.0% of patients in the HD-DXM arm and 41.2% in the PDN arm (P = 0.884). Initial complete response was a positive indicator of sustained response, whereas presence of anti-platelet autoantibodies was a negative indicator. High-dose dexamethasone was generally tolerated better. We concluded that high-dose dexamethasone could be a preferred corticosteroid strategy for first-line management of adult primary ITP. This study is registered at clinicaltrials.gov as NCT01356511.
Submitted July 22, 2015.
Accepted October 13, 2015.
Rob16 wrote: I just figured out something about dexamethasone. It has a very long half-life of 36-54 hours, which means that even though one typically takes it for four days, it remains effective for two weeks or more. What many people complain about as the "WITHDRAWAL" of dexamethasone may actually be the continued high levels of steroid. Because of its long half-life, dexamethasone is somewhat self-weaning.
The Platelet Disorder Support Association does not provide medical advice or endorse any medication, vitamins or herbs. The information contained herein is not intended nor implied to be a substitute for professional medical advice and is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment, discontinuing an existing treatment and to discuss any questions you may have regarding your unique medical condition.
Platelet Disorder Support Association
8751 Brecksville Road, Suite 150, Cleveland, Ohio 44141
Phone: 1-87-PLATELET | 877-528-3538 (toll free) | or 440-746-9003
E-mail: pdsa@pdsa.org
© Copyright 1997 - 2025, Platelet Disorder Support Association. All rights reserved.
The Platelet Disorder Support Association is a 501(c)3 organization and donations are tax deductible to the fullest extent allowed by law.